nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Additional Neurology Topics"

 

ADHD and Risk of Migraine
July 5, 2022   

A recent longitudinal case-cohort study shows children and adolescents with ADHD were associated with an increased risk of migraine compared with matched controls. Results showed that children and adolescents with ADHD were associated with an increased risk of migraine compared with...
 Continue reading (Members only)
Role Of The Oral-Gut-Microbiome-Brain Axis In Trauma-Related Disorders
February 23, 2022   

The microbiome-gut-brain axis has been proposed as a moderator or mediator for posttraumatic stress disorder (PTSD). However, clinical data about this direct relationship are lacking. In a recent cohort study, the associations between the gut microbiome and mental health outcomes...
 Continue reading (Members only)
Psilocybin Therapy Increases Cognitive And Neural Flexibility In Patients With Major Depressive Disorder
November 18, 2021   

Psilocybin therapy has shown promise in treating major depressive disorder and other psychiatric illnesses. However, the cognitive and neural mechanisms underlying its enduring efficacy is poorly understood. An open-label study examined the enduring effects of psilocybin therapy on the cognitive and neural flexibility...
 Continue reading
2021 NEI Congress Young Investigator Poster Competition Winners
November 5, 2021   

The 2021 NEI Congress Scientific Poster Session and Reception was held on Friday, November 5th and featured 67 posters, with an additional 48 posters presented virtually, covering the full spectrum of mental health research and clinical data. Among them, three particularly stood out for the quality of their data and contributions to the field, and...
 Continue reading
Fluoxetine and Post-Stroke Depression
August 30, 2021   

One in 3 adults suffer clinically significant symptoms of depression for the first year following a stroke. There is limited evidence that supports the use of antidepressants in this population. A recent parallel-group, randomized, double-blind...
 Continue reading (Members only)
Psychotropic Polypharmacy Prevalent in Patients With Dementia
March 25, 2021   

Dementia is increasingly prevalent as the population ages. In addition to memory deficits, patients with dementia often exhibit other neuropsychiatric symptoms that can be disturbing to caregivers and increase the likelihood of institutionalization. It is therefore not uncommon for patients with dementia to be prescribed psychotropic agents despite...
 Continue reading (Members only)
Task Force Tackles FDA Lamotrigine Cardiac Risk Warning
March 12, 2021   

Recently, the International League Against Epilepsy and the American Epilepsy Society Task Force met to discuss the food and drug administration warning on the cardiac effects of lamotrigine. These concerns originated from lamotrigine’s sodium channel blocking properties....
 Continue reading
COVID-19 Effects in the Brain
January 14, 2021   

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is associated with a host of symptoms related to the central nervous system, it is unclear if SARS-CoV-2 can penetrate the brain-blood barrier (BBB). A study by...
 Continue reading (Members only)
Risk of Mental Illness Following COVID-19
November 23, 2020   

Aside from severe physical illness and potential death, one of the issues of great concern with SARS-CoV2 (COVID-19) infection is the effect of COVID-19 infection of mental health. In this network cohort study examining electronic health record data from 69 million individuals...
 Continue reading
2020 NEI Max! Highlight: What to Do When Your Patient is Using Methamphetamine
November 7, 2020   

Inspired by audience questions at NEI live meetings over recent years, ‘Breaking Bad: What To Do When Your Patient is Using Methamphetamine’ was developed to address the numerous clinical scenarios that can be complicated by methamphetamine use and abuse...
 Continue reading
123456
Top of Page